Trends in Net Survival from Vulvar Squamous Cell Carcinoma in Italy (1990-2015).
Silvia ManciniLauro BucchiFederica ZamagniFlavia BaldacchiniEmanuele CrocettiOrietta GiulianiAlessandra RavaioliRosa VattiatoMario PretiRosario TuminoStefano FerrettiAnnibale BiggeriPaola BallotariLorenza BoschettiAngelita BrustolinAdele CaldarellaRossella CavalloClaudia CirilliAnnarita CitarellaMaria L ContrinoLuigino Dal MasoRosa Angela FilibertiMario FuscoRocco GalassoFernanda L LottiMichele MagoniLucia MangoneGiuseppe Michele MasanottiGuido MazzoleniWalter MazzuccoAnna MelcarneMaria MichiaraPaola PesceAngela PintoDaniela PirasRoberto V RizzelloMagda RognoniStefano RossoMassimo RuggeGiuseppe SampietroSanto ScalziTiziana ScuderiGiovanna TagliabueFederica ToffoluttiSusanna VitarelliFabio Falcininull nullPublished in: Journal of clinical medicine (2023)
(1) Objective: In many Western countries, survival from vulvar squamous cell carcinoma (VSCC) has been stagnating for decades or has increased insufficiently from a clinical perspective. In Italy, previous studies on cancer survival have not taken vulvar cancer into consideration or have pooled patients with vulvar and vaginal cancer. To bridge this knowledge gap, we report the trend in survival from vulvar cancer between 1990 and 2015. (2) Methods: Thirty-eight local cancer registries covering 49% of the national female population contributed the records of 6274 patients. Study endpoints included 1- and 2-year net survival (NS) calculated using the Pohar-Perme estimator and 5-year NS conditional on having survived two years (5|2-year CNS). The significance of survival trends was assessed with the Wald test on the coefficient of the period of diagnosis, entered as a continuous regressor in a Poisson regression model. (3) Results: The median patient age was stable at 76 years. One-year NS decreased from 83.9% in 1990-2001 to 81.9% in 2009-2015 and 2-year NS from 72.2% to 70.5%. Five|2-year CNS increased from 85.7% to 86.7%. These trends were not significant. In the age stratum 70-79 years, a weakly significant decrease in 2-year NS from 71.4% to 65.7% occurred. Multivariate analysis adjusting for age group at diagnosis and geographic area showed an excess risk of death at 5|2-years, of borderline significance, in 2003-2015 versus 1990-2002. (4) Conclusions: One- and 2-year NS and 5|2-year CNS showed no improvements. Current strategies for VSCC control need to be revised both in Italy and at the global level.
Keyphrases
- papillary thyroid
- squamous cell carcinoma
- squamous cell
- dengue virus
- lymph node metastasis
- healthcare
- clinical trial
- free survival
- ejection fraction
- randomized controlled trial
- quality improvement
- computed tomography
- newly diagnosed
- radiation therapy
- early stage
- locally advanced
- prognostic factors
- case report
- young adults
- case control
- zika virus
- contrast enhanced